A healthcare editorial illustration highlighting Eli Lilly's expanded special access program for its experimental weight loss medication.

Eli Lilly Weight Loss Drug: More Patients Can Now Apply for Special Access

Eli Lilly has confirmed it will open the door for more patients to apply for early, pre-approval access to retatrutide, its next-generation obesity drug that has shown weight loss results rivaling bariatric surgery. The announcement, made on August 3, 2026, comes just weeks after it was revealed that Lilly had already granted one such "compassionate use" request to a single, well-connected patient — a move that drew scrutiny once other doctors learned about it and began asking for the same opportunity for their own patients.

For the millions of Americans living with obesity who have been closely watching retatrutide's development, this expanded access announcement is a significant, if limited, development. It doesn't mean the drug is approved or widely available — but it does open a new, narrow pathway for a select group of patients to potentially receive the medication before it reaches pharmacy shelves.

Here's what's actually happening, why it matters, and what patients and doctors need to understand about this expanded access program.

What Is Retatrutide?

Retatrutide is Eli Lilly's experimental obesity treatment and one of the most closely watched drugs in the weight-loss category. It belongs to the same general class of therapies as Lilly's already-approved medications Zepbound and Mounjaro, but it's designed to act on multiple hormone receptors at once, which researchers believe is part of why its results have been so striking in clinical trials.

In trial data released earlier this year, retatrutide helped participants lose an average of roughly 30% of their body weight after 104 weeks — a level of weight loss historically associated with bariatric surgery rather than medication. More recent data from an 80-week trial involving adults with severe obesity and established heart disease showed average weight loss of 22.6% at the highest weekly dose tested.

Because of these results, retatrutide has generated enormous anticipation. Lilly has said it plans to submit an FDA approval application for the drug in the first quarter of 2027, after previously suggesting a submission could come by the end of 2026. The company said it needed additional time to gather manufacturing and quality-control data required by regulators.

How the Expanded Access Story Began

The current expanded access announcement traces back to a single, unusual case. According to reporting from STAT News, Eli Lilly and the FDA allowed a 79-year-old man to access retatrutide through the FDA's "compassionate use" program — officially known as expanded access — a regulatory pathway that allows patients with serious or immediately life-threatening conditions to receive experimental treatments outside of clinical trials.

What made this case unusual wasn't just the compassionate use approval itself, but the circumstances surrounding it. Sources familiar with the matter said the request drew interest from top health officials, suggesting the recipient was well connected. The identity of the patient was not confirmed publicly, but the case raised questions in the medical community about fairness and access — namely, why should one patient receive early access to a potentially life-changing drug while others with similarly serious conditions could not?

After that story became public, doctors representing other patients began reaching out to Lilly to ask whether similar access could be arranged for their own patients. Some doctors reportedly did not receive a response for weeks. It was only after STAT asked Lilly directly about these unanswered requests that the company confirmed, on August 3, 2026, it would formally open the door to additional applications.

What Eli Lilly's Expanded Access Program Actually Covers

Eli Lilly has described the program as being available to "a limited number of patients" who meet specific medical criteria and are unable to enroll in an ongoing clinical trial. According to a company spokesperson, Lilly built this expanded access framework specifically to accommodate patients in this situation, consistent with FDA guidance on expanded access programs.

The eligibility criteria Lilly has outlined include:

• The patient must be 18 years of age or older
• The patient must have refractory obesity — meaning their obesity has not responded adequately even while tolerating the highest approved dose of existing obesity therapy
• The patient must have at least two serious or life-threatening obesity-related complications for which they are currently receiving medical care
• The patient must be unable to enroll in an ongoing clinical trial for retatrutide

In other words, this is not a general early-access program for anyone eager to try the drug before its official launch. It is specifically designed for patients with severe, treatment-resistant obesity and significant related health complications — people for whom existing FDA-approved options have already been tried and have not sufficiently worked.

Lilly says it is "actively reviewing requests from health care providers," which means the application process runs through a patient's physician rather than through a direct-to-consumer channel. Patients interested in this pathway cannot apply on their own; a treating doctor must submit the request to Lilly on their behalf.

Why This Matters: The Bigger Picture on Obesity Drug Access

This expanded access announcement doesn't exist in a vacuum. It comes amid a broader, ongoing push by Eli Lilly to widen access to its obesity medicines across multiple fronts — not just for unapproved drugs like retatrutide, but for its already-approved treatments too.

In November 2025, Lilly announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs, including new lower pricing for a Zepbound multi-dose pen. And earlier this year, Lilly's CEO said Medicare's expanded coverage of obesity treatments could dramatically widen access to the company's oral weight-loss pill, orforglipron, once it launches, potentially unlocking eligibility for tens of millions of Medicare beneficiaries.

Separately, in June 2026, Lilly rolled out details of a Medicare GLP-1 Bridge program, giving eligible Medicare Part D patients access to certain weight-management medications, including orforglipron and Zepbound, starting July 1, 2026, and running through the end of 2027.

Taken together, these moves reflect a company under significant public and competitive pressure to demonstrate that its next generation of obesity treatments will be broadly accessible — not just to the wealthy or well-connected, but to a wide range of patients who genuinely need them. The retatrutide expanded access controversy, in particular, highlighted a fairness gap that Lilly appears eager to address before it becomes a bigger public relations or regulatory problem.

What This Means for Patients Hoping to Access Retatrutide

If you or someone you know is living with severe, treatment-resistant obesity and hoping to explore early access to retatrutide, here are a few important realities to understand:

1. This is not a general prescription pathway. Expanded access programs are narrow by design and reserved for patients who meet strict medical criteria and cannot join a clinical trial.
2. Your doctor has to initiate the request. Patients cannot apply directly to Lilly; a treating physician must submit the application on the patient's behalf.
3. Approval is not guaranteed. Even patients who meet the stated criteria may not be approved, since Lilly is reviewing requests on a case-by-case basis with a limited program.
4. This is different from full FDA approval. Even with expanded access opening up, retatrutide is still an unapproved drug. Lilly does not expect to file its full FDA approval application until the first quarter of 2027, and approval itself would likely take additional time after that.
5. Clinical trials remain another option. For patients who don't qualify for expanded access but want a chance to try retatrutide sooner, enrolling in an ongoing clinical trial may be a more accessible route, depending on trial eligibility criteria and location.

A Word of Caution About Unauthorized Access

One important subtext to this story is that some patients, frustrated by the wait for FDA approval, have reportedly tried to obtain retatrutide through unofficial or unverified channels rather than through legitimate clinical or expanded access programs. Medical experts have repeatedly warned that acquiring experimental drugs outside of regulated pathways carries serious risks, including the possibility of counterfeit or improperly manufactured products, incorrect dosing, and a lack of medical oversight during treatment.

Anyone considering retatrutide, or any other unapproved medication, should pursue it only through legitimate, physician-supervised channels — whether that's a clinical trial or, for a small number of eligible patients, the expanded access program Lilly has now confirmed it will broaden.

What Happens Next

With Lilly's FDA application for retatrutide expected in the first quarter of 2027, the coming months will likely bring more clarity on both the drug's regulatory timeline and how the expanded access program is being administered in practice. Given the scrutiny the program has already received following the initial compassionate use case, it's reasonable to expect continued media and regulatory attention on how fairly and transparently Lilly manages requests going forward.

For now, patients with severe, treatment-resistant obesity and significant related health complications who are interested in retatrutide should speak with their physician about whether they might meet the criteria for expanded access, or whether an ongoing clinical trial might be a better fit for their situation.

Frequently Asked Questions

What is retatrutide? Retatrutide is an experimental obesity drug developed by Eli Lilly that has shown weight loss results in clinical trials comparable to bariatric surgery. It is not yet approved by the FDA.

Who can apply for expanded access to retatrutide? Patients aged 18 or older with refractory obesity, at least two serious or life-threatening obesity-related complications, and who cannot enroll in a clinical trial may be eligible. A treating physician must submit the request on the patient's behalf.

Why did Eli Lilly expand this access program now? The move follows public reporting that Lilly had already granted compassionate use access to a single, well-connected 79-year-old patient, which prompted other doctors to request similar access for their patients.

When will retatrutide be approved by the FDA? Eli Lilly plans to file its FDA approval application in the first quarter of 2027. Full approval, if granted, would likely follow sometime after that submission.

Is expanded access the same as buying the drug commercially? No. Expanded access is a narrow, physician-initiated pathway for specific patients with serious unmet medical needs. It is separate from commercial availability, which will only follow full FDA approval.

Final Thoughts

Eli Lilly's decision to open early access to retatrutide to more patients marks a notable, if narrow, shift in how the company is handling demand for one of the most anticipated obesity drugs in development. While it won't meaningfully change access for most people hoping to try the medication before its expected 2027 approval timeline, it does address a fairness concern that emerged after reports of a single, seemingly well-connected patient receiving early access. As retatrutide moves closer to its FDA submission, expect continued attention on how Lilly balances patient need, program integrity, and public trust — all while racing to bring one of its most promising obesity treatments to market.